Vestal Point Capital, LP Astria Therapeutics, Inc. Transaction History
Vestal Point Capital, LP
- $1.9 Trillion
- Q2 2025
A detailed history of Vestal Point Capital, LP transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Vestal Point Capital, LP holds 4,522,000 shares of ATXS stock, worth $30.1 Million. This represents 1.28% of its overall portfolio holdings.
Number of Shares
4,522,000
Previous 4,180,000
8.18%
Holding current value
$30.1 Million
Previous $22.3 Billion
8.59%
% of portfolio
1.28%
Previous 1.59%
Shares
5 transactions
Others Institutions Holding ATXS
# of Institutions
110Shares Held
49.3MCall Options Held
6.6KPut Options Held
0-
Perceptive Advisors LLC New York, NY6.49MShares$43.1 Million1.53% of portfolio
-
Fcpm Iii Services B.V. Naarden, P74.11MShares$27.3 Million6.34% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$23.6 Million5.84% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$23.4 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.97MShares$19.7 Million0.01% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $101M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...